TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) — SEC Financial Statements & Analysis

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is a pharmaceutical preparations company, incorporated in L3. TEVA PHARMACEUTICAL INDUSTRIES LTD trades on NYSE, OTC as: TEVA, TEVJF. TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-29. Based on that filing, TEVA PHARMACEUTICAL INDUSTRIES LTD carries a market cap of $39.47B, a P/E ratio of 55.67x, a P/B ratio of 5.09x, a P/S ratio of 2.28x, an enterprise value of $40.32B, and an EV/EBITDA multiple of 15.56x. On profitability, it posts a gross margin of 52.46%, an operating margin of 9.26%, a net margin of 4.09%, a Return on Equity (ROE) of 9.73%, a Return on Assets (ROA) of 1.77%, and a Return on Invested Capital (ROIC) of 21.89%. Per share, it reports EPS of $0.61, diluted EPS of $0.61, free cash flow per share of $1.16, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 4.13% year-over-year, net income growth of -250.21% year-over-year, and EPS growth of -247.89% year-over-year. On the balance sheet, it maintains a current ratio of 0.88x, a quick ratio of 0.61x, working capital of $-1.89B, a debt-to-equity ratio of 4.14x, a debt ratio of 0.81, free cash flow of $1.35B (TTM), and net debt of $845.00M. Figures sourced from SEC EDGAR.

Market Cap

$39.47B

P/E TTM

55.67x

EPS TTM

$0.61

P/B TTM

5.09x

ROE TTM

9.73%

ROA TTM

1.77%

Debt To Equity

4.14x

Free Cash Flow TTM

$1.35B

Net Revenue TTM Growth 1Y

4.13%

Data as of 2026-06-30 · Source: SEC EDGAR